Results for Ipilimumab and Nivolumab Following Autologous Stem Cell Transplant in Multiple Myeloma

In the first article of a 2-part series, Jack Khouri, MD, discussed the challenges that come with the toxicity profile of selinexor and how physicians can manage these adverse events.

In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, delves further into the background of momelotinib, how to manage toxicities with the agent, and its role in clinical practice moving forward.

In an interview with Targeted Oncology, Arlene O. Siefker-Radtke, MD, discusses the findings from 3 trials of erdafitinib and explains the next steps for evaluating the agent.

In the second article of a 2-part series, Ajay Nooka, MD, MPH, discussed the exciting safety profile of teclistamab and how to manage major adverse events, like cytokine release syndrome, for patients with relapsed/refractory multiple myeloma.

In an interview with Targeted Oncology, Sara A. Hurvitz, MD, discusses the impact of trastuzumab deruxtecan, new developments, and unmet needs in the HER2-positive breast cancer space.

In an interview with Targeted Oncology, Jeffrey R. Schriber, MD, highlighted some of the most recent updates in the field of multiple myeloma, and discussed emerging therapies that show promise.